HUADONG MEDICINE(SZ:000963)2022-12-07 08:48Financial Performance - In 2014, the company achieved a revenue of CNY 18.947 billion, representing a year-on-year growth of 13.34% [3] - The net profit attributable to shareholders was CNY 757 million, with a year-on-year increase of 31.60% [3] - The rapid profit growth was primarily due to the continuous sales growth of core pharmaceutical subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [3] Pharmaceutical Business Development - The main products of Zhongmei Huadong, including Bai Ling capsules and Acarbose, saw sales growth exceeding 30% [4] - The sales of Pantoprazole increased by over 20%, while the overall sales of immunosuppressants surpassed CNY 600 million, with a growth rate of around 20% [4] - The company faced significant price pressure in the bidding process for essential medicines, particularly for Bai Ling capsules [4] E-commerce and Market Expansion - The company has actively expanded its e-commerce business, launching a flagship store on Alibaba's Tmall [6] - Over 300 retail pharmacies in Hangzhou, including 20 stores under the company, signed agreements with Ali Health to participate in the electronic prescription platform [6] - The overall business volume from e-commerce remains small and has no significant impact on the company's performance [6] Research and Development - The company completed 12 research project applications in 2014, focusing on enhancing R&D project management and efficiency [6] - The Acarbose chewable tablet successfully passed the new drug application production review and received production approval in February 2015 [7] - The company is optimistic about the future development of Acarbose series products and has also received clinical approval for the new drug Maihuatini for treating advanced non-small cell lung cancer [7]